|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Uveitis or retinitis pigmentosa? Ester Carreño, MD, PhD, on mimics
2
EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease
3
EURETINA 2026: Gene therapy sessions to watch in Vienna
4
What retinal imaging reveals about the brain-eye connection with Sharon Fekrat, MD, FACS, FASRS
5












